Insider Selling: Oscar Health (NYSE:OSCR) Insider Sells 395,000 Shares of Stock

Key Points

• Oscar Health insider Mario Schlosser sold 395,000 shares of the stock at an average price of $18.43, reducing his position by 44.08%.
• The company's recent earnings report showed a loss of ($0.89) per share with a revenue of $2.86 billion, reflecting a 29.0% year-over-year increase.
• Analysts have downgraded Oscar Health’s stock ratings, with a consensus target price lowered to $12.07 and a majority rating of "Strong Sell".

Oscar Health, Inc. (NYSE:OSCR - Get Free Report) insider Mario Schlosser sold 395,000 shares of the stock in a transaction dated Monday, September 22nd. The stock was sold at an average price of $18.43, for a total transaction of $7,279,850.00. Following the sale, the insider owned 501,148 shares of the company's stock, valued at $9,236,157.64. This trade represents a 44.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Oscar Health Price Performance

Shares of NYSE:OSCR traded up $0.64 on Wednesday, reaching $18.40. 15,509,409 shares of the company were exchanged, compared to its average volume of 14,027,844. The company has a 50-day moving average of $16.31 and a 200-day moving average of $15.30. Oscar Health, Inc. has a 1-year low of $11.20 and a 1-year high of $22.78. The company has a current ratio of 0.86, a quick ratio of 0.86 and a debt-to-equity ratio of 0.26. The firm has a market cap of $4.76 billion, a price-to-earnings ratio of -22.71 and a beta of 1.87.

Oscar Health (NYSE:OSCR - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported ($0.89) earnings per share for the quarter, topping the consensus estimate of ($0.90) by $0.01. The firm had revenue of $2.86 billion for the quarter, compared to the consensus estimate of $2.88 billion. Oscar Health had a negative return on equity of 13.78% and a negative net margin of 1.50%.The firm's revenue for the quarter was up 29.0% compared to the same quarter last year. During the same period in the prior year, the business posted $0.20 earnings per share. Equities analysts forecast that Oscar Health, Inc. will post 0.69 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in OSCR. Osaic Holdings Inc. boosted its holdings in Oscar Health by 285.6% during the second quarter. Osaic Holdings Inc. now owns 186,997 shares of the company's stock worth $4,009,000 after purchasing an additional 138,505 shares during the last quarter. Straightline Group LLC boosted its holdings in Oscar Health by 3.7% during the second quarter. Straightline Group LLC now owns 18,082 shares of the company's stock worth $388,000 after purchasing an additional 640 shares during the last quarter. Marex Group plc purchased a new position in Oscar Health during the second quarter worth about $266,000. State of Wyoming boosted its holdings in Oscar Health by 564.7% during the second quarter. State of Wyoming now owns 112,146 shares of the company's stock worth $2,404,000 after purchasing an additional 95,274 shares during the last quarter. Finally, Hollencrest Capital Management purchased a new position in Oscar Health during the second quarter worth about $64,000. 75.70% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

OSCR has been the topic of a number of research analyst reports. Wall Street Zen lowered shares of Oscar Health from a "hold" rating to a "sell" rating in a research note on Saturday, August 9th. Baird R W cut shares of Oscar Health from a "strong-buy" rating to a "hold" rating in a research report on Friday, July 25th. Robert W. Baird reaffirmed a "neutral" rating and set a $14.00 price objective (down from $28.00) on shares of Oscar Health in a research note on Friday, July 25th. UBS Group reiterated a "sell" rating and issued a $11.00 target price (down previously from $15.00) on shares of Oscar Health in a research note on Tuesday, July 15th. Finally, Barclays dropped their price target on Oscar Health from $17.00 to $11.00 and set an "underweight" rating for the company in a report on Wednesday, July 23rd. Four research analysts have rated the stock with a Hold rating and five have assigned a Sell rating to the company. According to data from MarketBeat, Oscar Health has an average rating of "Strong Sell" and a consensus target price of $12.07.

Oscar Health Company Profile

Oscar Health, Inc operates as a health insurance in the United States. The company offers health plans in individual and small group markets, as well as +Oscar, a technology driven platform that help providers and payors directly enable their shift to value-based care. It also provides reinsurance products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.